Goldman Sachs Group Inc Lineage Cell Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 180,189 shares of LCTX stock, worth $320,736. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180,189
Previous 350,103
48.53%
Holding current value
$320,736
Previous $157,000
3.82%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding LCTX
# of Institutions
141Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$88.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.1 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$12.1 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.6 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $302M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...